Storage & Thawing Protocol
To ensure the quality, viability, and purity of our products, AllCells adheres to a consistent method for cell storage and thawing. By strictly following an in-depth, step-by-step protocol, AllCells’ clients can depend on reliable results. Continue reading for additional precautions and safety advisories.
To determine the number of viable cells in a given sample, researchers need to utilize a proven protocol for precisely counting their cells. AllCells has developed a protocol that is based on scientifically-proven techniques and methods for counting cells.
Shipping & Delivery Options
Product integrity, delivery speed, and optimized pickup times – AllCells’ shipping principles. To deliver on these principles, AllCells utilizes an industry-leading AeroSafe Global Shipping Package, customer-focused delivery options, and an optimized processing schedule. You can trust AllCells to deliver the highest quality cells on time and on your schedule.
Preclinical Assessment of AMG 596, a Bispecific T-cell Engager (BiTE) Immunotherapy Targeting the Tumor-specific Antigen EGFRvIII
Alexander Sternjak, Fei Lee, Oliver Thomas, Mercedesz Balazs, Joachim Wahl
AMG 596 is a bispecific T-cell engager (BiTE) immuno-oncology therapy in clinical development for treatment of glioblastoma multiforme (GBM), the most common primary brain tumor in adults with limited therapeutic options. AMG 596 is composed of two single-chain variable fragments that simultaneously bind to the tumor-specific antigen, EGFR variant III (EGFRvIII), on GBM cells and to CD3 on T cells...
Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease
Claire L. Langrish, J. Michael Bradshaw, Michelle R. Francesco, Timothy D. Owens
Bruton tyrosine kinase (BTK) is expressed in B cells and innate immune cells, acting as an essential signaling element in multiple immune cell pathways. Selective BTK inhibition has the potential to target multiple immune-mediated disease pathways. Rilzabrutinib is an oral, reversible, covalent BTK inhibitor designed for immune-mediated diseases. We examined the pharmacodynamic profile of rilzabrutinib and its preclinical...
How Can We Help You?
Looking for research tips? Need help sourcing materials? How about a few more articles on therapies or processes? At AllCells, we believe that partnerships create the best pathways to success. Our Customer Success Team has years of industry experience and a wealth of resources to help you get the most out of your cellular products. We’re only a few clicks away.
Subscribe to Our Blog
Stay current with the AllCells Blog. Get email updates with helpful resources for biomedical researchers: